Overview

* AbCellera Q2 2025 revenue of $17.1 mln beats analyst expectations, per LSEG data

* Net loss narrows to $34.7 mln from $36.9 mln in Q2 2024

Result Drivers

* REVENUE GROWTH - Revenue increased to $17.1 mln, driven by higher licensing revenue

* STRONG LIQUIDITY - Over $750 mln in available liquidity supports ongoing strategy

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $17.10 $6.12

Revenue mln mln (6

Analysts

)

Q2 Net -$34.70

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Abcellera Biologics Inc ( ABCL ) is $9.00, about 54.2% above its August 6 closing price of $4.12

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)